COUMADIN can cause fetal harm when administered to a pregnant woman. While COUMADIN is contraindicated during pregnancy, the potential benefits of using COUMADIN may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism . In those individual situations, the decision to initiate or continue COUMADIN should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patient’s medical situation, as well as the most current medical guidelines. COUMADIN exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage , and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use In Specific Populations ].
===Name of drug=== *Will be capitalized if it is a trade name (brand name) or uncapitalized if it is a generic name. *Two trade names that are nearly identical (eg Adalat PA and Adalat XL) need not have separate entries unless there is a particular reason for doing so. *Names will be listed alphabetically and broken into an appropriate number of pages (with 200-500??? items per page) Peg-Intron is the correct spelling that you have listed as Pegetron for pegylated interferaon alfa2b made by schering plough and marketed in the US for HCV